Background: The hormone adiponectin (APN) was initially extracted from the fat cells of rats. Widespread interest was piqued in this messenger's potential role in establishing communication between adipose tissue and other metabolically relevant organs. In addition to boosting insulin sensitivity and inducing apoptosis in cancer cells, APN also acts as an antioxidant and anti-inflammatory. Seventy percent of all occurrences of dementia are due to Alzheimer's disease (AD), making it the most prevalent form of age-related neurodegeneration. Objective: Review of the literature on adiponectin possible role among Alzheimer's disease. Methods: We looked for data on Adiponectin, Aging and Alzheimer's disease in medical journals and databases like PubMed, Google Scholar, and Science Direct. However, only the most recent or extensive study was taken into account between August 2011 and April 2021. References from related works were also evaluated by the writers. There are not enough resources to translate documents into languages other than English, hence those documents have been ignored. It was generally agreed that documents such as unpublished manuscripts, oral presentations, conference abstracts, and dissertations did not qualify as legitimate scientific study. Conclusion: Aging, and particularly in chronic APN deficient subjects, appears to cause neurodegenerative alterations such as memory and learning impairment, anxiety, and atypical dread. The hallmarks of AD include increased microgliosis, astrogliosis, and cerebral IL1β as well as TNFα. The ageing of APN knock-out mice was accompanied with dysregulation of insulin signaling activity in the brain and decreased insulin sensitivity in the hippocampi.